Fig. 3

Efficacy, adverse events, and survival outcome of bispecific antibody treatment and ICI combination therapies in patients with Lung cancer. a A histogram depicting the antitumor efficacy of BSABs and ICIs combination therapies in patients with lung cancer, including various subgroups. The ORR, defined as a sum of CR and PR. pCR, pathological CR; ALK, anaplastic lymphoma kinase; wt, wild-type; mut, mutation; N3I1q12w, 3 mg/kg Nivo q2w plus 1 mg/kg Ipi q12w; N3I1q6w, 3 mg/kg Nivo q2w plus 1 mg/kg Ipil q6w; N1I3, 1 mg/kg Nivo plus 3 mg/kg Ipi; bTMB, blood tumor mutation burden; mut/mb, mutations per megabase; chemo, chemotherapy; Trem, Tremelimumab (anti-CTLA-4); Durv, Durvalumab (anti-PD-1); Triago, Tiragolumab (anti- TIGIT); Atezo, Atezolizumab (anti- PD-L1). b A forest plot charting the survival outcomes of BSABs and ICIs combination therapies in patients with lung cancer. c A histogram depicting the incidence of grade ≥ 3 AEs, as well as major compositions of grade ≥ 3 TRAEs in patients with lung cancer treated with BSABs and ICIs combination therapies. A bar with a value of 0 means not mentioned in the article